Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2005-04-18 | Mr. Herbert H. McDade, Jr. was elected to be one of our directors in 1988. He is Chairman of the Compensation Committee of the Board. Each director who is not our employee receives a quarterly fee of $3,000 and $1,000 per quarter per committee (aggregate for all committees) in which he/she is a member. |
| 2006-04-25 | Mr. McDade was a member of the Compensation Committee of the Board. |
| 2007-04-13 | Mr. Herbert H. McDade, Jr. has served as one of our directors since 1988 and was previously a member of the Compensation Committee of the Board. ... The Compensation Committee was composed of Herbert H. McDade, Jr., Jeffrey B. Davis, J. Michael Flinn and Stephen B. Howell, MD. ... The table below represents the compensation paid to our directors during the year ended December 31, 2006: Herbert H. McDade, Jr.: Fees earned or Paid in Cash ($) 17,200, Option Awards ($) 6,137, Total ($) 23,338. |
| Filing Date | Source Excerpt |
|---|---|
| 2001-04-24 | Herbert H. McDade, Jr. (74) first became a director of CytRx in 1990. Mr. McDade has been retired from business since 1996. From 1989 to 1996 Mr. McDade served as Chairman, President and Chief Executive Officer of Chemex Pharmaceuticals, Inc. (now Access Pharmaceuticals, Inc.). From 1986 to 1989 he was Chairman and President of Armour Pharmaceutical Corporation, a wholly-owned subsidiary of Rorer Group, Inc. (now Rhone-Poulenc Rorer). |
Data sourced from SEC filings. Last updated: 2025-08-30